Alpha-MSH Analogue Therapy for Vitiligo Repigmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vitiligo, such as phototherapy and topical corticosteroid therapy, have limitations including the need for repetitive exposure to UV light, which can cause side effects like skin irritation and increased risk of skin malignancies, and long-term use can lead to skin thinning and other issues.
Innovation Solution
A pharmaceutical composition comprising an alpha-MSH analogue, either alone or in combination with corticosteroids, immunosuppressants, anti-inflammatory agents, and photochemotherapeutic agents, administered to treat or prevent vitiligo, potentially used in conjunction with narrow band ultraviolet B (NB UVB) light exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phototherapy with narrow band UV-B light is used to treat vitiligo, then skin repigmentation is achieved, but repetitive exposure causes skin irritation, burning, blistering and increases risk of skin malignancies
Solution Approach 1:
The patent changes the therapeutic parameter from UV-B light exposure to topical application of corticosteroids and immunosuppressants, fundamentally altering the treatment mechanism to avoid phototoxicity while maintaining repigmentation effectiveness
Solution Approach 2:
The patent introduces corticosteroids and immunosuppressants as intermediary substances that mediate the treatment process, suppressing autoimmune attack on melanocytes without requiring direct UV light exposure, thereby eliminating skin damage risks
2Reliability
If topical corticosteroid therapy is used to treat vitiligo, then repigmentation success rate reaches up to 56%, but long-term use causes skin thinning, stretch marks and blood vessel dilation
Solution Approach 1:
The patent combines multiple treatment modalities (corticosteroids, immunosuppressants, and phototherapy) into a single comprehensive treatment protocol, allowing each component to be used at optimized doses that reduce individual side effects while maintaining overall effectiveness
Solution Approach 2:
The patent employs periodic or intermittent treatment cycles with corticosteroids and immunosuppressants, alternating with phototherapy sessions, which reduces cumulative exposure and minimizes long-term skin damage while maintaining treatment efficacy
3Reliability
If oral or topical psoralen plus UVA (PUVA) therapy is used, then treatment success is achieved, but long term use increases incidence of skin cancer
Solution Approach 1:
The patent changes the photochemical treatment parameter from high-dose PUVA therapy to controlled narrow band UV-B phototherapy combined with topical agents, reducing the cumulative DNA damage that leads to skin cancer while maintaining repigmentation success
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition promotes melanin production and skin repigmentation with reduced risk of side effects compared to existing treatments, offering a more effective and safer option for vitiligo management.
Implementation Method 1
a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue... for the treatment or prevention of vitiligo... promotes melanin production and skin repigmentation
Implementation Method 2
phototherapy involves exposing an individual to narrow band UV-B light (NB-UVB) resulting in skin repigmentation
Data Source
AI summary
The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.